(July 14, 2016, 11:44 AM EDT) -- WILMINGTON, Del. — On the eve of the expiration of a 30-month stay of approval by the U.S. Food and Drug Administration of an abbreviated new drug application (ANDA) for generic Savella, a fibromyalgia drug, a Delaware federal judge on July 11 deemed the proposed generic an infringement of three patents and concluded that the same three patents are valid (Forest Laboratories Holdings Ltd., et al. v. Mylan Pharmaceuticals Inc., et al., No. 13-1602, D. Del.; 2016 U.S. Dist. LEXIS 89268)....